PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Bortezomib

Drugs in development · updated 30 October 2026

Bortezomib: clinical trials and development status

Other names and codes: Velcade

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 26 April 2004

As of 30 October 2026 Bortezomib is in 142 active clinical trials (recruiting or ongoing, phases I–III) for 41 diseases. The most advanced phase is III.

142Active trials
IIIMost advanced phase
41Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Bortezomib and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 41 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Multiple myelomaIII86NCT05519085
Immunoglobulin Light-chain AmyloidosisIII8NCT07901725
Precursor lymphoblastic lymphoma/leukemiaIII7NCT03643276
Plasma cell neoplasmIII6NCT06152575
AmyloidosisIII5NCT07901725
LymphomaII–III5NCT07072585
Precursor T-cell lymphoblastic leukemiaIII4NCT02112916
Hematologic neoplasmIII3NCT07635511
ParaproteinemiaIII2NCT04504825
LeukemiaII–III1NCT03117751
Mantle cell lymphomaII4NCT04626791
Acute myeloid leukemiaI–II3NCT07008638
NeoplasmII3NCT00092222
Graft-versus-host diseaseI–II2NCT07675174
Waldenstrom MacroglobulinemiaII2NCT00492050
Acute biphenotypic leukaemiaII1NCT06390319
Autoimmune diseaseII1NCT03993262
Autoimmune disease of the nervous systemII1NCT03993262
Autoimmune thrombocytopenic purpuraII1NCT05599880
Beta thalassemiaII1NCT05736419
Burkitt lymphomaII1NCT03136146
EncephalitisII1NCT03993262
GlioblastomaI–II1NCT03643549
HIV infectionII1NCT00092222
LymphadenopathyII1NCT00092222
Lymphoproliferative disordersII1NCT00092222
Multi-centric Castleman's DiseaseII1NCT00092222
Non-Hodgkin lymphomaI–II1NCT04068597
Pancreatic neoplasmI–II1NCT06572813
Peripheral T-cell lymphomaI–II1NCT04068597

Everything on Bortezomib

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch